Trial Profile
Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Feb 2022
Price :
$35
*
At a glance
- Drugs Valbenazine (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 31 Oct 2019 Status changed from recruiting to completed.
- 27 Feb 2018 New trial record